Article Information
History
- March 31, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Debra Van Egeren1,2,
- Madison Stoddard3,
- Abir Malakar4,5,
- Debayan Ghosh5,
- Antu Acharya5,
- Sk Mainuddin5,
- Biswajit Majumdar5,
- Deborah Luo6,
- Ryan Nolan7,
- Diane Joseph-McCarthy8,
- Laura F. White8,
- Natasha S. Hochberg9,10,
- Saikat Basu4 and
- Arijit Chakravarty3,*
- 1Weill Cornell Medicine, New York, NY, USA
- 2New York Genome Center, New York, NY, USA
- 3Fractal Therapeutics, Cambridge, MA, USA
- 4South Dakota State University, Brookings, SD, USA
- 5Jadavpur University, Kolkata, WB, India
- 6Amity Regional High School, Woodbridge, CT, USA
- 7Halozyme Therapeutics, San Diego, CA, United States of America
- 8Boston University, Boston, MA, USA
- 9Boston University School of Medicine, Boston, MA, USA
- 10Boston Medical Center, Boston, MA, USA
- ↵*Corresponding author; email: arijit{at}fractaltx.com
Posted March 31, 2022.
No magic bullet: limiting in-school transmission in the face of variable SARS-CoV-2 viral loads
